[go: up one dir, main page]

MX2021004211A - Composiciones vacuna. - Google Patents

Composiciones vacuna.

Info

Publication number
MX2021004211A
MX2021004211A MX2021004211A MX2021004211A MX2021004211A MX 2021004211 A MX2021004211 A MX 2021004211A MX 2021004211 A MX2021004211 A MX 2021004211A MX 2021004211 A MX2021004211 A MX 2021004211A MX 2021004211 A MX2021004211 A MX 2021004211A
Authority
MX
Mexico
Prior art keywords
vaccine compositions
protecting
useful
relates
human subject
Prior art date
Application number
MX2021004211A
Other languages
English (en)
Inventor
Alain Bouckenooghe
Remi Forrat
Jean Lang
Mélanie Saville
Nadia Tornieporth
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of MX2021004211A publication Critical patent/MX2021004211A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a composiciones de vacuna que son útiles en un método de protección de un sujeto humano contra la enfermedad del dengue.
MX2021004211A 2012-07-24 2015-01-09 Composiciones vacuna. MX2021004211A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305907 2012-07-24
EP12305912 2012-07-25

Publications (1)

Publication Number Publication Date
MX2021004211A true MX2021004211A (es) 2021-05-27

Family

ID=48875047

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015000442A MX381497B (es) 2012-07-24 2013-07-24 Composiciones vacuna.
MX2021004211A MX2021004211A (es) 2012-07-24 2015-01-09 Composiciones vacuna.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015000442A MX381497B (es) 2012-07-24 2013-07-24 Composiciones vacuna.

Country Status (12)

Country Link
US (2) US20150196631A1 (es)
EP (2) EP3932422A1 (es)
JP (2) JP2015524421A (es)
KR (2) KR20200067938A (es)
CN (1) CN104812407B (es)
AU (1) AU2013295014B2 (es)
CA (1) CA2878682A1 (es)
MX (2) MX381497B (es)
MY (2) MY168959A (es)
PH (1) PH12014502840B1 (es)
SG (2) SG10201912291YA (es)
WO (1) WO2014016360A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013295016A1 (en) * 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
CA2903231A1 (en) 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
CN107405392B (zh) * 2015-02-09 2021-05-18 中央研究院 用于增强对抗登革病毒的安全性及免疫力的抗原表位替换的疫苗
BR112017028212A2 (pt) * 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
EP3147294B1 (en) * 2015-09-24 2020-04-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing dengue virus infections from other flaviviral infections using a recombinant mutant envelope protein
JP6910956B2 (ja) * 2015-11-27 2021-07-28 Ｋｍバイオロジクス株式会社 デングウイルス弱毒株をバンク化した生ウイルス、及びそれらを抗原とするデングワクチン
CN109069615B (zh) * 2016-04-13 2025-03-04 武田疫苗股份有限公司 在儿童和年轻人中针对登革热病毒接种疫苗的组合物和方法
WO2018208741A1 (en) 2017-05-08 2018-11-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
EP3691681A1 (en) * 2017-10-05 2020-08-12 Sanofi Pasteur Compositions for booster vaccination against dengu
WO2019113285A2 (en) 2017-12-06 2019-06-13 Emory University Zika vaccines and methods of use
EP3549603A1 (en) 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
AU2019335006B2 (en) 2018-09-05 2024-07-04 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
CN116334070A (zh) * 2023-02-15 2023-06-27 天津大学 融合蛋白的应用和细胞融合的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US109A (en) 1836-12-15 Erawijtg
US5422A (en) 1848-02-01 Spark-arrester
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
AU740961B2 (en) 1997-02-28 2001-11-15 Sanofi Pasteur Biologics Co. Chimeric flavivirus vaccines
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2365728A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
WO2000057904A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-3 virus vaccine
WO2000057910A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
AU4040200A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
AU3844101A (en) 2000-02-16 2001-08-27 Us Health Avirulent, immunogenic flavivirus chimeras
PT1159968E (pt) 2000-05-30 2008-11-20 Univ Mahidol Estirpes atenuadas de vírus do dengue e a sua utilização numa composição de vacina
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
EP2290108B1 (en) 2001-05-22 2014-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
CN1551782A (zh) 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
CA2473321C (en) * 2002-01-15 2015-10-06 Acambis, Inc. Flavivirus vaccines
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
BRPI0613328A2 (pt) * 2005-06-17 2011-01-04 Sanofi Pasteur cepa do vìrus da dengue-1 vivo atenuado, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada e fragmento de poliproteìna
CA2611954C (en) 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
BRPI0614265A2 (pt) 2005-08-10 2011-03-22 Acambis Inc uso de uma vacina do vìrus da febre amarela e de uma vacina de flavivìrus quimérico e kit contendo referidas vacinas
JP5138601B2 (ja) * 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition

Also Published As

Publication number Publication date
AU2013295014B2 (en) 2018-01-18
JP2019151636A (ja) 2019-09-12
JP2015524421A (ja) 2015-08-24
US20150196631A1 (en) 2015-07-16
EP2877208B1 (en) 2021-05-12
EP3932422A1 (en) 2022-01-05
CN104812407A (zh) 2015-07-29
PH12014502840A1 (en) 2015-02-23
SG10201912291YA (en) 2020-02-27
MY197723A (en) 2023-07-10
JP6830118B2 (ja) 2021-02-17
WO2014016360A1 (en) 2014-01-30
MY168959A (en) 2019-01-28
CA2878682A1 (en) 2014-01-30
KR20150036592A (ko) 2015-04-07
PH12014502840B1 (en) 2015-02-23
MX2015000442A (es) 2015-03-12
KR20200067938A (ko) 2020-06-12
US20190201517A1 (en) 2019-07-04
AU2013295014A1 (en) 2015-01-29
MX381497B (es) 2025-03-12
CN104812407B (zh) 2022-11-22
SG11201500412TA (en) 2015-02-27
EP2877208A1 (en) 2015-06-03
HK1212906A1 (zh) 2016-06-24

Similar Documents

Publication Publication Date Title
MX2021004211A (es) Composiciones vacuna.
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
SG11201604697TA (en) Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
GB2501611B (en) Alpha-2-macroglobulin compositions and therapeutic uses
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
EP2895139A4 (en) COMPOSITIONS AND METHODS FOR DENTAL TREATMENT
ZA201408056B (en) Compositions and methods for the treatment of mucositis
IL237431A0 (en) Immunogenic preparations
GB201310150D0 (en) Methods and compositions relating to alzheimer's disease
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
IL236636A0 (en) Difluorolactam formulations for ep4-mediated bone-related conditions and diseases
IL241555B (en) Preparations for the treatment of xerostomia and dental care
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
GB201210397D0 (en) Crop enhancement compositions
ZA201503844B (en) Compositions and methods for treating dental caries
EP2883433A4 (en) Tiller tine
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
IL217807A0 (en) Therapeutic compositions
EP2914233A4 (en) DENTAL COMPOSITIONS
IN2012DE00826A (es)
HUE065064T2 (hu) HMB-t éa ATP-t tartalmazó készítmények és felhasználásuk
IN2015MN00091A (es)
SG11201505170WA (en) Dengue virus vaccine composition
GB201210395D0 (en) Crop enhancement compositions
GB201216054D0 (en) Hair restoration